We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy


Critical Raw Material for mRNA-Based Vaccine Development


Critical Raw Material for mRNA-Based Vaccine Development

Who's speaking at this Webinar?

Andrius Kocevas
Product Manager

Accelerated development of mRNA-based vaccine has necessitated the transformation of standard, research grade in vitro transcription reagents into raw material specifically designed and manufactured under advanced quality standards. The TheraPure grade reagents for mRNA-based vaccine represents Thermo Fisher Scientific’s highest level of purity for mRNA synthesis reagents, with products manufactured using high-definition analytics and tightly controlled purity standards. The TheraPure grade portfolio offers a unique integrated solution for mRNA synthesis, including animal origin-free and ampicillin-free enzymes.

In this webinar we will discuss:

  • The quality requirements for critical raw material for commercial mRNA production
  • Ongoing projects to optimize the entire mRNA portfolio to meet fit-for-purpose standards


Like what you just read? You can find similar content on the communities below.

Genomics Research Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free